At-home urine test spots bladder cancer in nine of ten NHS cases
New CapabilitiesGALEAS Bladder caught 92% of cancers in a 964-patient trial and could cut the need for invasive cystoscopy
Today: Trial results published: 92.2% of bladder cancers detectedNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 1 hour agoA urine test patients can take at home caught more than nine in ten bladder cancers in an NHS trial of 964 patients. The GALEAS Bladder test detected all muscle-invasive cancers and carried a 99.3% chance the patient was clear when it returned a negative result.
The test reads DNA shed into urine for mutations across 23 genes linked to bladder cancer. It works as a triage tool: a positive result pushes patients to the front of the line for urgent cystoscopy, while a negative result lets lower-risk patients defer the invasive camera procedure.
Why it matters
A UK-wide rollout could spare thousands of patients a year an invasive camera test and cut six-week waits many now face for a bladder cancer diagnosis.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
Led the 964-patient multicenter study validating GALEAS Bladder in real-world NHS haematuria clinics.
Birmingham-based biotech that developed and sells GALEAS Bladder.
Regional NHS body that commissioned the test for all hospital trusts in the West Midlands by April 2027.
Timeline
October 2024 April 2027
-
West Midlands targets full regional adoption
Upcoming MilestoneAll hospital trusts in the West Midlands are expected to offer GALEAS Bladder, per West Midlands Cancer Alliance commissioning.
-
Trial results published: 92.2% of bladder cancers detected
Today PublicationStudy shows GALEAS caught 71 of 77 cancers, all muscle-invasive tumors, and carried a 99.3% negative predictive value.
-
First NHS trust in England adopts GALEAS Bladder
RolloutUniversity Hospitals of Leicester becomes the first English trust to use the test; five hospitals have adopted it, 16 more planned.
-
Trial completes enrollment at 964 patients
Study milestoneEnrollment ends; 77 of 964 patients are ultimately diagnosed with bladder cancer.
-
Multicenter trial begins in seven NHS urology departments
Study launchUniversity of Birmingham study starts enrolling patients referred for urgent haematuria investigation.
Historical Context
2 moments from history that rhyme with this story — and how they unfolded.
HPV DNA testing replaces cytology in cervical screening (2000s)
For decades, cervical cancer screening relied on the Pap smear, a subjective microscope examination of cells. The FDA approved the first HPV DNA test for co-testing in 2003, and by 2014 an HPV test was approved as a primary screening option.
Clinics could triage women by infection status, cutting unnecessary procedures and repeat tests.
Molecular testing became the standard of care, showing that objective DNA-based tests can outperform subjective cytology in population screening.
GALEAS Bladder follows the same arc: an objective DNA test replacing a subjective, invasive procedure, with triage as the initial use case.
Cologuard stool DNA test approved for colorectal cancer (2014)
The FDA approved Exact Sciences' Cologuard, an at-home stool test detecting DNA mutations and blood markers for colorectal cancer. It gave patients a non-invasive alternative to colonoscopy screening.
Millions of patients who avoided colonoscopy could screen at home with a mail-in kit.
Cologuard validated the regulatory and reimbursement path for at-home molecular cancer tests, later expanding to broader multi-cancer detection.
GALEAS Bladder mirrors the Cologuard model: a home-administered DNA test that triages who truly needs an invasive scope, reducing procedural burden.
